Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don Mahad

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Brain : a Journal of Neurology|December 15, 2025
A cause and protective treatment for acute and progressive disability and grey matter atrophyErika A Aguzzi, Roshni A Desai, Zhiyuan Yang, et al.
The American Journal of Pathology|January 28, 2003
CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophagesCorinna Trebst, Susan M Staugaitis, Pia Kivisäkk, et al.
Brain : a Journal of Neurology|October 19, 2005
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesisDon Mahad, Melissa K Callahan, Katherine A Williams, et al.
Nature|May 25, 2012
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrityUrsula Fünfschilling, Lotti M Supplie, Don Mahad, et al.
Nature Metabolism|July 10, 2023
Targeting the TCA cycle can ameliorate widespread axonal energy deficiency in neuroinflammatory lesionsYi-Heng Tai, Daniel Engels, Giuseppe Locatelli, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2020
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosisNick Cunniffe, Khue Anh Vuong, Debbie Ainslie, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Brain : a Journal of Neurology|December 15, 2025
A cause and protective treatment for acute and progressive disability and grey matter atrophyErika A Aguzzi, Roshni A Desai, Zhiyuan Yang, et al.
The American Journal of Pathology|January 28, 2003
CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophagesCorinna Trebst, Susan M Staugaitis, Pia Kivisäkk, et al.
Brain : a Journal of Neurology|October 19, 2005
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesisDon Mahad, Melissa K Callahan, Katherine A Williams, et al.
Nature|May 25, 2012
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrityUrsula Fünfschilling, Lotti M Supplie, Don Mahad, et al.
Nature Metabolism|July 10, 2023
Targeting the TCA cycle can ameliorate widespread axonal energy deficiency in neuroinflammatory lesionsYi-Heng Tai, Daniel Engels, Giuseppe Locatelli, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2020
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosisNick Cunniffe, Khue Anh Vuong, Debbie Ainslie, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 3